Astellas Pharma (JP:4503) has released an update.
Astellas Pharma has withdrawn its marketing application for avacincaptad pegol, a treatment for geographic atrophy linked to age-related macular degeneration, from the European Medicines Agency. Despite positive results in the U.S., the company cites interactions with the EMA as the reason for this decision, while remaining optimistic about the drug’s clinical benefits and committed to global regulatory engagement.
For further insights into JP:4503 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
